The COMparison of CALcium Bioavailability Between AlgaeCal® and a Proprietary Supplement (COMCAL)
|ClinicalTrials.gov Identifier: NCT01609413|
Recruitment Status : Completed
First Posted : June 1, 2012
Last Update Posted : June 1, 2012
In a crossover, single blind, randomized trial the calcium bioavailability of two calcium supplements will be compared.That is AlgaeCal®(Algaecal Inc, Vancouver, Canada)(1 dose is 3 capsules of 180 mg calcium), derived from ocean algae and the proprietary calcium supplement Caltrate 600® (Wyeth Consumer Healthcare, Inc).
After a screening visits 20 healthy male subjects aged 20-50 years will spend a day at the research center to examine calcium bioavailability data. They will be randomized to consume either first the AlgaeCal® supplement or the Caltrate 600® supplement. After a one week wash-out period subjects will be supplemented with the other supplement. During the examination day blood and urine samples will be collected before and until eight hours after the supplementation for analyses of calcium, creatinine, phosphorus, albumin and 25 Hydroxy vitamin D. Subjects are instructed to avoid taking calcium and/or vitamin D supplements 1 week before and during the entire study period. In addition, they are not allowed to take medication that may affect calcium metabolism.
The hypothesis of the study is that calcium bioavailability of the AlgaeCal® supplement will be higher than that of the Caltrate 600® supplement.
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Dietary Supplement: AlgaeCal Dietary Supplement: Caltrate 600||Phase 1|
This was a single centre, single-dose, randomized, two way cross-over study in healthy male subjects.
The study consisted of the following visits:
- A screening visit to select eligible subjects according to the inclusion/exclusion criteria detailed in the study protocol.
- Visit 1 in which subjects who satisfied the selection criteria were assigned to one of the two intervention sequences (Algaecal®/ LCCS or LCCS/Algaecal®) according to the randomization list;
- Visit 2, after at least one week of wash-out in respect to visit 1. Subjects arrived at the centre early in the morning The first blood sample was drawn before the ingestion of the calcium supplement and every hour after for the following 8 hours. Urine sample were collected before the ingestion of the calcium supplement and every 2 hours after for the following 8 hours. During each study visit the subjects were present in the site centre from the morning to the evening. Calcium supplement was given under fasted condition and during the eight hours after the product ingestion, according to the protocol, only water ad libitum was allowed.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Official Title:||A Human Crossover Study to Compare the Bioavailability of Calcium From AlgaeCal® Versus a Proprietary Calcium Dietary Supplement|
|Study Start Date :||October 2009|
|Primary Completion Date :||April 2010|
|Study Completion Date :||April 2010|
Calcium supplements derived from ocean algae. One dose equals 3 capsules containing 180 mg calcium each.
Dietary Supplement: AlgaeCal
One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
Active Comparator: Caltrate 600
Proprietary calcium supplement. One dose contains 600 mg of calcium.
Dietary Supplement: Caltrate 600
One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
- Will be measured the oral bioavailability of calcium from a single dose of AlgaeCal® (Algaecal, Vancouver, Canada) compared to a proprietary calcium supplement (Caltrate 600®, Whyett Consumer healthcare, Inc). [ Time Frame: one day ]During the examination day blood and urine samples will be collected before and untill eight hours after the supplementation for analyses of calcium, creatinine, phosphorus, albumin and 25 Hydroxy vitamin D.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01609413
|Luigi Sacco Hospital|
|Milan, Italy, 20157|
|Principal Investigator:||Emilio Clementi, Prof||University of Milan, Milan, Italy|